what is microdose glp 1 Microdosing GLP-1 Medications Noom Launches Microdose GLP-1 Program,

GLP-1 treatments like Wegovy, Zepbound, Mounjaro, and compounded Semaglutide and Tirzepatide are helping people see real, lasting weight loss results, often without the need for surgery

By balancing the potential benefits and risks of treatment using evidence-based strategies, HCPs are well placed to help optimise the use of GLP-1 RAs in the management of obesity and overweight

Mounjaro may be the better choice if: You need treatment now (retatrutide is not yet available) You prefer a medication with extensive real-world safety data Your BMI qualifies you for current GLP-1 prescriptions You have type 2 diabetes (Mounjaro has robust diabetes data) You are sensitive to GI side effects and want a well-established titration protocol Your weight loss goals are achievable with 15 to 22% body weight reduction You want insurance coverage options (available for some plans) Mounjaro is the proven, accessible, right-now option

OSAS has a high prevalence and significant adverse consequences

15 In the SURPASS-1 study, tirzepatide monotherapy at increasing doses of 5, 10, and 15 mg resulted in significant weight loss of 7, 7.8, and 9.5 kg, respectively, at week 40 in patients with T2DM, compared with a 0.7 kg decrease with placebo